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In this review we consider the current evidence base for treatments in inflammatory eye disease, and in particular
uveitis, from a historical perspective. We consider the challenges that have traditionally hindered progress in
inflammatory eye disease including small target populations, heterogeneous disease groups, poorly defined
phenotypes, diagnostic inconsistency, subjective outcome measures, specific issues around visual acuity as an
outcome measure and low commercial interest. Strategies to address these issues are considered de novo and with
reference to recent advances outside of ophthalmology and highlight the promise for ocular inflammation.
Progress in these specialties has included the development of thriving clinical-trial cultures, public-private
partnerships, pathogenetic- and structure-led drug design, efficient drug development pipelines, and biomarker-
defined treatment protocols enabling personalization of medicine. Although there are challenges, these are exciting
opportunities as we seek to develop safe and effective treatments for patients with inflammatory eye disease.Introduction
Philosophically we recognize that the past informs our
present but realize less that our present actions and
thoughts dictate our future. To this end, as we consider
the progress that has been made in the systemic treat-
ment of inflammatory eye disease, there is a danger that
we over-value recent successes due to their proximity
rather than merit. Newer drugs, like most recent news
stories, may attract more of the reviewer’s attention: they
are the recent arrivals, usually accompanied by a prom-
ise of delivering better outcomes for our patients and
with the advantage of having had time to demonstrate
their short-term efficacy but not their long-term conse-
quences (whether good or ill). Objective assessment of
the merits of these systemic therapies requires the high-
quality evidence that comes from well-designed random-
ized clinical trials, with extended follow-up to ensure
late effects are not missed. We are currently a long way
from being in that position. In the clinic we are inured
to this and, on the basis of the limited available evidence
alongside experience and anecdote [1], we make the best
therapeutic choice we can. We are reassured because* Correspondence: a.denniston@bham.ac.uk
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distribution, and reproduction in any mediumcohort studies infer that a majority of patients improve
[2-8], but we do not know whether to what extent a pla-
cebo or indeed no treatment would have had the same
effect. This is clearly an unsatisfactory position and we
need to move on.
In this review we have not sought to appraise the indi-
vidual systemic therapies currently available to us; this is
important but is covered in detail elsewhere [9,10].
Rather we seek to provide a critical assessment of the
state of the field: where we started from, what progress
has been made and a vision of how we can bridge the
considerable gap to get to where we need to be – pro-
viding therapies which are proven to be effective and
safe and targeted to the individual patient in front of us.
Looking back: dark ages to the renaissance
A characteristic of our medical past was that, though
well-motivated by a desire to provide better care to our
patients, actual therapeutic practice was often driven
more by personality and confidence rather than by care-
ful study and appraisal. Thus up to the early 20th
century the therapeutic armory of the physician included
useless or harmful practices such as bleeding, purging,
and widespread provision of tonics, mercuric com-
pounds and hypnotics. Patients with ocular inflamma-
tion were similarly provided for. In the 18th century a
popular propriety remedy ‘Golden Eye Ointment’ was aCentral Ltd. This is an Open Access article distributed under the terms of the
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and was promoted as being useful for ‘all forms of
chronic ophthalmia’. In the late 19th century, Savory's
Compendium of Domestic Medicine recommended “In
inflammation of the eye, originating from cold or acci-
dent, it is advisable to apply three or four leeches round
the orbit… they will always be found to be safe, and
generally a successful remedy [11].” Rather more useful
was the application of tincture of belladonna to induce
pupil dilation. In the 1930s the advent of commercially
available antibiotics heralded the start of rational treat-
ment for infectious eye disease, but also gave some indi-
cation that much inflammatory eye disease was actually
non-infectious in origin. It was recognized then that
non-infectious inflammatory eye disease would require
an entirely different therapeutic approach.
In 1950 the use of corticosteroids for chronic anterior
uveitis by Gordon and McLean signaled a major break-
through in the management of inflammatory eye disease
[12]. With high efficacy and fast onset of action, cortico-
steroids quickly established their role in the acute treat-
ment of inflammatory disease (i.e. induction of remission)
but their wide-ranging systemic side-effects have always
limited their long-term usage (i.e. for maintenance of
remission). The latter half of the 20th century saw the
introduction of immunosuppressants such as the alkylat-
ing agents (cyclophosphamide [13,14] and chlorambucil),
the antiproliferative agents (including methotrexate [15],
azathioprine [16] and mycophenolate [17]) and the
calcineurin antagonists (notably ciclosporin [18] and
tacrolimus [19]). This was a revolution in our approach to
therapeutics, representing a new paradigm of understand-
ing immune mechanisms in animal models, using these
animal models as a translational path to provide evidence
to move into man and finally conducting early proof of
concept studies [18,20-24]. Although slower in onset and
requiring more intensive monitoring than corticosteroids,
these agents were generally more suitable for maintenance
therapy due to their improved systemic safety profile, pro-
viding that they were monitored appropriately [17,19,25].
However, these agents, like corticosteroids, lack specificity.
They cause a generalized immunosuppression which
renders the patient more vulnerable to opportunistic and
severe infection. Although some success has been achieved,
a more targeted approach was sought.
The advent of biologic medical products (‘biologics’)
has been a major landmark in the treatment of inflam-
matory disease. Drugs such as the anti-TNF agents (e.g.
etanercept, infliximab, adalimumab) and the anti-CD20
agent rituximab have already revolutionized the manage-
ment of many rheumatic diseases, and the impact is now
being realized within ophthalmology. The development
of a biologic should arise out of a knowledge of the
pathogenesis of the inflammatory disease, and betargeted to inhibit or modulate specific components.
This approach has been taken for uveitis with the poten-
tial to be more effective in controlling disease with less
impact on the patient’s overall health. Leading the
charge within ophthalmology are the anti-TNF therapies.
We among others have undertaken a program of work
which has investigated the role of TNF-α in the patho-
genesis of uveitis [26], leading to the development of an
anti-TNF-α fusion protein (TNFr-Ig) in 1996 which we
evaluated first in an animal model of uveitis [27,28], and
subsequently in a Phase II/proof of concept clinical trial
in 2004 [4,29]. In this study, 71% of the patients
achieved complete cessation of intraocular inflammation
following TNFr-Ig therapy and a reduction in concomi-
tant immunosuppression was possible in 65% of cases
[29]. Importantly TNFr-Ig therapy appeared to be effect-
ive across uveitic subtypes, including Behçet’s disease,
idiopathic intermediate uveitis, multifocal choroiditis
and sympathetic ophthalmia. These findings are sup-
ported by a large body of work from other groups
[30-35], and subsequent reviews and editorials have
highlighted the impact of anti-TNF-α therapies in oph-
thalmic practice [7,36-39].
These are exciting times with an ever-expanding range
of immunosuppressants on the FDA-approved list. But
the question remains: how much progress have we actu-
ally made? Put another way, when faced with a patient
with sight-threatening inflammatory eye disease, do we
actually know which drug to use?
Most of the immunosuppressants used in ocular
inflammatory disease were originally developed for use
in transplant medicine, rheumatic disease or other
systemic inflammatory diseases. Very few have high level
evidence for their use in ocular inflammation, and
almost all are used off-label. A recent study which sur-
veyed uveitis experts’ approach to a number of clinical
scenarios, found that whilst there was a general consen-
sus on the overall approach to immunosuppression (i.e.
starting with corticosteroids first line, and subsequent
initiation of a steroid-sparing immunosuppressant) there
was considerable variation in which second line agent to
use and at what dose. This is perhaps unsurprising since
the study also reported that these experts suggested the
evidence underlying their decisions was either absent or
relatively weak (evidence levels III or IV based on the
evidential hierarchy described by the United States
Agency for Health Care Policy and Research) [40], and
that in most cases personal experience was a key factor
in their decision-making [1]. In this regard we should
not under-estimate recent progress which has seen an
increasing number of prospective studies on standard
and novel therapies [41-45], and larger standardized
retrospective studies [2-8]. A balanced approach is
needed. Our current shortage of large-scale randomized
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evidence that is already available for therapeutic efficacy
and safety. Conversely we must recognize the ‘evidence-
gap’ that remains and identify strategies that will enable
us to bridge it.
There are a number of reasons we lag behind other
specialties, notably our small target population, hetero-
geneous disease groups, poorly defined phenotypes,
uncertain pathogenesis, diagnostic inconsistency, sub-
jective outcome measures, visual acuity issues, and until
recently little commercial interest and a non-trial cul-
ture. These are some of the factors that need to be
addressed if we are to conduct the trials and build the
evidence base which will enable us to make informed
therapeutic decisions in the future.
Reflecting on now: the Age of enlightenment
In most ‘inflammologies’ (rheumatology, renal medicine
and the rest) the last decade has been characterized by
major multicentre studies that have established the effi-
cacy and safety of established or novel therapies in a
randomized controlled format (vs. placebo or standard
care). In inflammatory eye disease we have performed
very few such studies, but encouragingly there has been
a major effort to address the blocks that have hitherto
limited our progress. A striking characteristic of this
new phase is the extent to which the whole inflamma-
tory eye disease community is working together with in-
creasing international and cross-specialty collaboration.
As we consider these issues below we have focused on
uveitis, but the arguments apply equally well to most
other forms of inflammatory eye disease (such as ocular
mucous membrane pemphigoid, autoimmune keratitis,
scleritis, myositis, inflammatory orbitopathies and in-
flammatory neuropathies):
Problem 1: small target population
Uveitis has an annual incidence of 14–50 per 100 000
[46], with a prevalence of around 38–115 per 100 000 in
the general population [47-49]. Since the majority of
these cases are acute anterior uveitis responsive to top-
ical therapy, the population of patients who need sys-
temic therapy (and are eligible for clinical trials of
immunosuppressants) is small. Other inflammatory dis-
eases such as scleritis have a higher proportion requiring
systemic therapy, but are overall much less common. It
is partly in response to this, that increasing collaboration
has emerged in recent years. One example is the SITE
consortium, a collaboration of five academic ocular in-
flammation practices in the United States who under-
took a retrospective cohort study primarily to investigate
long-term adverse events occurring in patients on
systemic therapies for ocular inflammatory disease;
although not the primary aim, this study also providesinteresting data on outcomes in the use of these drugs
[50]. The study group comprised 7957 (of whom 2340
were treated with systemic immunosuppression) patients
observed over 68751 visits, spanning 14.910 person years
[2-6]. Whilst accepting the limitations inherent in a
retrospective study, this is an important milestone in be-
ing the largest dataset of immunosuppression in ocular
inflammatory disease.
Problem 2: heterogeneous disease groups
Ocular inflammatory disease is very heterogeneous group.
Within uveitis, classification is generally by anatomical
grouping and etiology, including the presence or absence
of systemic disease. ‘Splitting’ i.e. defining a very pure co-
hort (e.g. Posterior uveitis of Birdshot pattern) leads to a
very small target population, whereas ‘lumping’ enables
easier recruitment but may be clinically meaningless due
to the range of disease included. This is true both for rou-
tine clinical practice and for clinical trials. In clinical trials
maximization of the signal: noise ratio is critical. An inter-
vention may be highly effective for a disease but will fail to
return a statistically significant benefit if it is trialed on too
broad a group of patients (e.g. patients who have condi-
tions that look superficially similar but differ fundamen-
tally in etiology).
Problem 3: poorly defined phenotypes
In addition to its heterogeneity as a group, the uveitis
subtypes are imperfectly defined with no diagnostic cri-
teria with high enough sensitivity and specificity to reli-
ably separate all cases of one uveitis entity from another.
This leads to considerable variation in classification and
diagnosis. To some extent such markers may only be-
come apparent as we better understand disease etiology.
This has occurred in the field of retinal dystrophies
where there has been a shift from grouping by somewhat
arbitrary pictorial descriptions (e.g. butterfly-shaped
macular dystrophy) to defining disease by the gene
responsible (e.g. a peripherin/RDS retinal dystrophy).
This is important not only because it leads to a more
clear-cut and objective classification of disease, but also
because a classification based on real differences in
etiology is more likely to translate into an appropriately
targeted therapeutic approach.
Problem 4: diagnostic inconsistency
Within uveitis the definition of syndromes by pattern
and the lack of clear diagnostic markers leads to signifi-
cant variation between clinicians in the classification of
uveitis entities. Currently a major international collabor-
ation - the Standardization of Uveitis Nomenclature
consortium - is seeking to define classification criteria
for 28 different uveitis syndromes [51]. The consortium
have identified 194 uveitic terms and ‘dimensions’
Denniston and Dick BMC Ophthalmology 2013, 13:18 Page 4 of 8
http://www.biomedcentral.com/1471-2415/13/18including 87 unique terms that are specifically used by
uveitis specialists to describe signs and symptoms. These
were mapped to the 28 uveitic syndromes under consider-
ation. Currently 250 cases per uveitis syndrome are being
gathered which will be used to validate the mappings and
to form the basis of a classification criteria and a proposed
ontology for uveitis [52]. Although this system is based on
pattern rather pathogenesis, this project does have the po-
tential to significantly improve standardization of uveitis
classification with benefits for both clinical practice and
trials.Problem 5: subjective outcome measures
One of the advantages of managing inflammation in the
eye (as opposed to elsewhere in the body) is that the
transparent nature of the cornea and visual axis enables
us to see and score inflammatory activity and titrate
treatment accordingly. The flip-side is that we have ac-
cepted these same subjective activity indices in clinical
trials. Non-invasive technologies which can objectively
quantify the key parameters of cellular activity, flare and
vitreous haze are needed. With regard to the assessment
of AC flare, laser flare meters have potential but current
models are relatively time-consuming and cumbersome,
with some concerns over variability especially in the
non-ideal patient (e.g. posterior synechiae, patient mo-
bility). Some models have sought to also quantify cellular
activity but with limited success. With regard to the pos-
terior segment the NEI vitreous haze score described by
Nussenblatt et al. (which depends on the clinician scor-
ing the clarity of the optic disc which can be compared
to a standard set of photographs) is the key outcome
recognized by the FDA [53]. Although it is the gold-
standard, it has a number of limitations including that it
is (1) subjective [54]; (2) non-continuous, leading to very
large steps in disease activity between categories; (3)
poorly discriminatory at lower levels of vitreous haze,
with most cases of active uveitis being scored at 0.5+ or
1+; and (4) limiting of recruitment and sensitivity in a
clinical trial context (where a 2 point change is usually
required to be counted as a significant change).
An adaptation of this technique proposed by Davis and
colleagues is to score clarity on photographs (rather than
on the live biomicroscopic view of the NEI technique)
which can then be compared to a more extensive set of
reference images leading to a potentially more discrimin-
atory 0–9 score (vs. the 0, 0.5, 1, 2, 3 and 4 scale of the
SUN modification of the Nussenblatt) [55]. Overall how-
ever this is still a subjective technique and shares most of
the key limitations of the standard vitreous haze score. A
truly objective measure is likely to be based on quantifica-
tion of vitreous density or reflectivity using current or
future imaging technologies.Problem 6: the ‘distraction’ of visual acuity
Whilst it is absolutely right that our key aim is to retain
and restore vision, we must recognize that visual acuity
is a very poor marker of the efficacy of a drug in inflam-
matory eye disease. The impact of uveitis on visual acu-
ity will depend on both the activity of the disease and
the damage caused by the disease. Thus whilst vision
may improve due to treatment-induced improvement in
cystoid macular edema, vitritis, keratic precipitates and
aqueous clarity, this benefit may be obscured by loss of
vision due to cataract, band keratopathy, macular
scarring or even glaucoma. A further complexity arises
in that some of these types of damage are reversible
(notably cataract and band keratopathy) leading to the
slightly bizarre scenario that their correction has to be
specifically prohibited within most clinical trials. Add-
itionally it is impossible to accurately quantify the extent
to which each factor is contributing to the reduced
visual acuity. Although the clinician is used to making
these judgment calls every day in clinic - for example
when deciding the extent to which advancing cataract or
persistent cystoid macular edema is responsible for a fall
in vision – these estimates are very approximate and fre-
quently shown to be incorrect. It should also be recog-
nized that visual acuity is a subjective parameter which
despite every effort towards standardization may be
affected by factors such as patient mood, general health
and compliance. Visual outcome remains the core pur-
pose for clinical trials in inflammatory eye disease, but it
is less clear how it should be utilized as a trial endpoint.
The increasing and important focus on patient
reported outcome measures (PROMs) as a component
of clinical trials may start to capture some of these as-
pects of the overall benefit experienced by the patient. It
is encouraging that more recent clinical trials in uveitis
have often incorporated measures both of quality of life
and health utility. These include specific vision-related
quality of life measures (such as the 25-item NEI-Visual
Function Questionnaire, NEI-VFQ25 or the Vision-
related Quality of Life Core Measure, VCM-1) [56-61]
general health-related quality of life measure (such as
the short form-36, SF-36) [58,59,61,62] and health utility
measures (such as the EuroQol 5-dimension, EQ-5D,
and Visual Analogue Scores) [61,63].Problem 7: Low commercial interest
In the past pharmaceutical companies have shown little
interest in ocular inflammatory disease, partly due to the
relatively small market. Encouragingly the last decade has
seen a surge of interest with industry-sponsored studies of
both novel agents – such as the calcineurin antagonist
voclosporin and the anti-IL17 agent secukinumab – and of
novel routes for older drugs (e.g. intravitreal corticosteroid
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robust evidence of anti-TNF blockade.
Looking forward: industrial revolution to
information Age
Addressing the challenges outlined above will enable us
to design and conduct the clinical trials that will be able
to inform our therapeutic decisions in inflammatory eye
disease. In the meantime the bar is being raised. In this
last section we look at a couple of case-studies that high-
light some of the exciting developments that are leading
to major advances in other specialties.
Ivacaftor: detailed understanding of pathogenesis leads
to specific drug-design matched to carefully defined
disease groups
Cystic Fibrosis is a life-limiting multisystem disorder
arising from abnormal function or complete loss of func-
tion of the protein, Cystic Fibrosis Transmembrane Con-
ductance Regulator (CFTR). The CFTR is an ABC
transporter-class ion channel in epithelial cell mem-
branes which regulates the constituents of sweat, mucus
and digestive fluids (reviewed [64]). Although non-
specialists often regard CF as a single condition, there is
significant variation in the severity and organ systems
preferentially affected. Since identification of the CFTR
gene in 1989, it has become increasingly clear that a key
part of this variation in phenotype is dependent on the
specific mutation in the CFTR gene. G551D is a muta-
tion which affects around 5% of CF patients. Critically,
although the G551D mutation does cause impaired ion
transport of the CFTR, the CFTR protein is still
expressed on the surface of the epithelial cell [65]. It was
therefore postulated that it might be possible to inter-
vene in this subgroup of CF patients by using drugs that
potentiate the existing CFTR function. Increasing inter-
est led to the Cystic Fibrosis Foundation contributing an
estimated $75 million to support the development of
one such drug Ivacaftor (Kalydeco) by Vertex Pharma-
ceuticals. In 2011 two placebo-controlled clinical studies
comprising a total of 213 patients showed significant
and sustained improvement in lung function [66]. In
early 2012 Ivacaftor was approved by the FDA for use in
patients with the G551D mutation. Thus for the first
time there is a therapy which actually targets and
restores function within the abnormal protein in CF,
albeit in a carefully defined subgroup of the disease and
with an estimated annual cost of $294, 000 per patient.
Although posterior segment uveitis is probably more
heterogeneous than CF (at least in terms of etiology and
pathogenesis), one of the key lessons here is that the
development of drugs such as Ivacaftor is only possible
when there is accurate classification of subtypes of
disease based on real differences at the pathogenic level.Within ophthalmology we see this approach showing
promise in the field of retinal dystrophies where accurate
definition of genotype opens the possibility of targeted
gene therapy [67]. As our understanding of the patho-
genesis of the ocular inflammatory diseases improves,
therapeutically useful classification of disease should
follow.
Vemurafenib: established drug-development pipeline
enables rapid translation for patient benefit
Metastatic melanoma has a very poor prognosis with a
median survival of 8 to 18 months after diagnosis for
stage IV melanoma. In 2002 Davis et al. noted that
around half of melanomas have an activating mutation
in the B-RAF oncogene, a regulator of the MAP kinase
pathway that controls cell proliferation [68]. Subse-
quently it was shown that 90% of these mutations are of
the V600E type. In 2008 Tsai et al. published their
results documenting the targeted development of a spe-
cific inhibitor of the mutant V600E BRAF and its effects
on both melanoma cell lines and tumor xenograft
models [69]. In 2010 the first Phase I trial defined the
maximal tolerated dose and noted frequent tumor
responses [70]. In 2011 the first phase 2 and first phase
3 reported efficacy data, the latter demonstrating signifi-
cant benefits with a six month survival of 84% (vs. 64%
for standard treatment) and a 74% relative reduction in
death or disease progression compared to standard treat-
ment [71,72]. Later that same year the drug was
approved by the FDA for the treatment of late stage
melanoma, a development time of just nine years since
the original Davis paper.
Within uveitis, the recent development of the anti-
IL17 therapy secukinumab and rapid translation into
clinical trials for non-infectious posterior segment
disease is an encouraging example of how ocular inflam-
matory disease can start to benefit from established drug
development pipelines [73]. Although it is too early to
comment on whether secukinumab will be a major
chapter or only a foot-note in the management of
uveitis, its targeted development from animal model to
clinical trial has been a significant milestone within the
field.
I-SPY-2: adaptive trial design and public-private
partnership underpin innovative rolling drug-testing
program
I-SPY-2 is a phase II rolling drug screening program to
test new therapies for breast cancer [74]. The design has
six treatment arms, including an arm for standard ther-
apy. A key feature is that randomization is adaptive
(within biomarker subsets) whereby the probability of
being assigned to a particular treatment arm increases if
the outcome of the prior patients in the group was good
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replaced either because they show sufficient success to
graduate to a smaller, focused phase III study or because
they are terminated due to lack of benefit (based on
Bayesian predictions of success or futility). This design
means that the more successful a drug, the faster that it
will move through the screening process. It also means
that trial participants will tend to receive the more
effective treatments. Fewer patients are required (per
drug outcome) and it is predicted to be significantly
cheaper than standard single drug non-adaptive designs.
Up to 12 drugs will be tested through the I-SPY-2 pro-
gram. This study is a collaboration across the USA
between the National Cancer Institute, the FDA and
around 20 major cancer centers, with active engagement
by pharmaceutical companies who are providing their
drugs for free. There is a commitment to publish all key
trial results and the data arising from the trial will be
managed by the independent non-profit organization the
Foundation for the NIH. It is probably too early to judge
but if successful, I-SPY-2 could revolutionize our ap-
proach to clinical trials [75,76].
Conclusions: A Bright Future
This ‘alternative’ universe may currently seem a long
way off: a vibrant clinical-trial culture, public-private
partnerships, pathogenetic- and structure-led drug de-
sign, efficient drug development pipelines, biomarker-
defined treatment protocols enabling personalization of
medicine, and a bench-to-approval transit time of less
than ten years. The successes in other specialties show
that this is achievable. Reflecting on how far we have to
go helps set our priorities and targets. Progress is being
made, and it is our hope that these advances in patho-
genesis, disease classification, methodology and trial de-
sign supported by a new culture of collaboration will
finally enable us to treat patients with inflammatory eye
disease with systemic therapies that are effective, safe …
and proven.
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